These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

610 related articles for article (PubMed ID: 29283064)

  • 1. Glycogen Synthase Kinase-3β as a Putative Therapeutic Target for Bipolar Disorder.
    Dandekar MP; Valvassori SS; Dal-Pont GC; Quevedo J
    Curr Drug Metab; 2018; 19(8):663-673. PubMed ID: 29283064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
    Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
    Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lithium and valproate act on the GSK-3β signaling pathway to reverse manic-like behavior in an animal model of mania induced by ouabain.
    Valvassori SS; Dal-Pont GC; Resende WR; Jornada LK; Peterle BR; Machado AG; Farias HR; de Souza CT; Carvalho AF; Quevedo J
    Neuropharmacology; 2017 May; 117():447-459. PubMed ID: 27789311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic influences on response to mood stabilizers in bipolar disorder: current status of knowledge.
    Rybakowski JK
    CNS Drugs; 2013 Mar; 27(3):165-73. PubMed ID: 23378337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based design leads to the identification of lithium mimetics that block mania-like effects in rodents. possible new GSK-3beta therapies for bipolar disorders.
    Kozikowski AP; Gaisina IN; Yuan H; Petukhov PA; Blond SY; Fedolak A; Caldarone B; McGonigle P
    J Am Chem Soc; 2007 Jul; 129(26):8328-32. PubMed ID: 17552518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lithium and neuropsychiatric therapeutics: neuroplasticity via glycogen synthase kinase-3beta, beta-catenin, and neurotrophin cascades.
    Wada A
    J Pharmacol Sci; 2009 May; 110(1):14-28. PubMed ID: 19423950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycogen synthase kinase-3β activity and cognitive functioning in patients with bipolar I disorder.
    Munkholm K; Miskowiak KW; Jacoby AS; Vinberg M; Leme Talib L; Gattaz WF; Kessing LV
    Eur Neuropsychopharmacol; 2018 Mar; 28(3):361-368. PubMed ID: 29433844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycogen synthase kinase-3beta in the platelets of patients with mood disorders: effect of treatment.
    Pandey GN; Ren X; Rizavi HS; Dwivedi Y
    J Psychiatr Res; 2010 Feb; 44(3):143-8. PubMed ID: 19717166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valproate regulates GSK-3-mediated axonal remodeling and synapsin I clustering in developing neurons.
    Hall AC; Brennan A; Goold RG; Cleverley K; Lucas FR; Gordon-Weeks PR; Salinas PC
    Mol Cell Neurosci; 2002 Jun; 20(2):257-70. PubMed ID: 12093158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of Glycogen Content in Astrocytes via Cav-1/PTEN/AKT/GSK-3β Pathway by Three Anti-bipolar Drugs.
    Jia S; Li B; Huang J; Verkhratsky A; Peng L
    Neurochem Res; 2018 Aug; 43(8):1692-1701. PubMed ID: 29968232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of glycogen synthase kinase-3beta in schizophrenia.
    Koros E; Dorner-Ciossek C
    Drug News Perspect; 2007 Sep; 20(7):437-45. PubMed ID: 17992266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mood stabilizer lithium potentiates the antidepressant-like effects and ameliorates oxidative stress induced by acute ketamine in a mouse model of stress.
    Chiu CT; Scheuing L; Liu G; Liao HM; Linares GR; Lin D; Chuang DM
    Int J Neuropsychopharmacol; 2014 Dec; 18(6):. PubMed ID: 25548109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a glycogen synthase kinase-3β inhibitor that attenuates hyperactivity in CLOCK mutant mice.
    Kozikowski AP; Gunosewoyo H; Guo S; Gaisina IN; Walter RL; Ketcherside A; McClung CA; Mesecar AD; Caldarone B
    ChemMedChem; 2011 Sep; 6(9):1593-602. PubMed ID: 21732538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of neuropsychiatric drugs on glycogen synthase kinase-3 signaling.
    Sutton LP; Rushlow WJ
    Neuroscience; 2011 Dec; 199():116-24. PubMed ID: 22001305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: A review of the literature.
    Costemale-Lacoste JF; Guilloux JP; Gaillard R
    Encephale; 2016 Apr; 42(2):156-64. PubMed ID: 26995153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lithium and GSK-3β promoter gene variants influence cortical gray matter volumes in bipolar disorder.
    Benedetti F; Poletti S; Radaelli D; Locatelli C; Pirovano A; Lorenzi C; Vai B; Bollettini I; Falini A; Smeraldi E; Colombo C
    Psychopharmacology (Berl); 2015 Apr; 232(7):1325-36. PubMed ID: 25345732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lithium increases platelet serine-9 phosphorylated GSK-3β levels in drug-free bipolar disorder during depressive episodes.
    de Sousa RT; Zanetti MV; Talib LL; Serpa MH; Chaim TM; Carvalho AF; Brunoni AR; Busatto GF; Gattaz WF; Machado-Vieira R
    J Psychiatr Res; 2015 Mar; 62():78-83. PubMed ID: 25691093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3.
    Chen G; Huang LD; Jiang YM; Manji HK
    J Neurochem; 1999 Mar; 72(3):1327-30. PubMed ID: 10037507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons.
    Yasuda S; Liang MH; Marinova Z; Yahyavi A; Chuang DM
    Mol Psychiatry; 2009 Jan; 14(1):51-9. PubMed ID: 17925795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Search for a common mechanism of mood stabilizers.
    Harwood AJ; Agam G
    Biochem Pharmacol; 2003 Jul; 66(2):179-89. PubMed ID: 12826261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.